{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:35:56Z","timestamp":1767771356458,"version":"build-2238731810"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sleep Breath"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Solriamfetol is approved for use in the European Union to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). SURWEY characterized real-world evidence regarding physician initiation and titration strategies and patient experiences with solriamfetol. We report SURWEY data for patients with OSA and EDS in Germany (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200983).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SURWEY was a retrospective chart review conducted among physicians in Germany. Eligible patients were age\u2009\u2265\u200918 years who reached a stable solriamfetol dose and completed\u2009\u2265\u20096 weeks of treatment. Patients were grouped by solriamfetol initiation strategy: changeover, add-on, new-to-therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients\u2019 mean (SD) age was 49 (14) years. New-to-therapy was the most common initiation strategy. Solriamfetol was initiated at 37.5\u00a0mg\/day in most patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200957, 69%) and titrated in 53 patients (64%); 30 (57%) completed titration within 2 weeks. In a post-hoc analysis, mean (SD) Epworth Sleepiness Scale (ESS) score was 16.0 (3.2) at baseline and decreased by 5.4 (3.6) at final follow-up (~\u200916 weeks;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;.001). Improvement in patient- and physician-rated EDS was reported by ~\u200990% of patients. Most patients (55%) reported effects of solriamfetol lasting\u2009\u2265\u20098\u00a0h; 91% of patients reported no change in nighttime sleep quality. The most frequent adverse events were headache (8%), decreased appetite (7%), and insomnia (6%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most patients in this study were new to therapy. Solriamfetol was typically initiated at 37.5\u00a0mg\/day; titration was common. ESS scores improved with solriamfetol treatment, and most patients self-reported improvement in EDS symptoms. Common adverse events were consistent with those reported in previous clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11325-025-03275-6","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:23:54Z","timestamp":1740738234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-4038","authenticated-orcid":false,"given":"Yaroslav","family":"Winter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Benes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Burghaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Floam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Parks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Kallweit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"3275_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.sleep.2016.02.008","volume":"23","author":"J Zhou","year":"2016","unstructured":"Zhou J, Camacho M, Tang X, Kushida CA (2016) A review of neurocognitive function and obstructive sleep apnea with or without daytime sleepiness. Sleep Med 23:99\u2013108. https:\/\/doi.org\/10.1016\/j.sleep.2016.02.008","journal-title":"Sleep Med"},{"key":"3275_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.sleep.2022.02.015","volume":"92","author":"U Kallweit","year":"2022","unstructured":"Kallweit U, Pevernagie D, Lammers GJ (2022) Sleepiness in obstructive sleep apnea: getting into deep water. Sleep Med 92:64\u201366. https:\/\/doi.org\/10.1016\/j.sleep.2022.02.015","journal-title":"Sleep Med"},{"key":"3275_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/jsr.12039","volume":"22","author":"M Gasa","year":"2013","unstructured":"Gasa M, Tamisier R, Launois SH, Sapene M, Martin F, Stach B, Grillet Y, Levy P, Pepin JL, Pneumology, -FFP SCotSRotFFo (2013) Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure. J Sleep Res 22:389\u2013397. https:\/\/doi.org\/10.1111\/jsr.12039","journal-title":"J Sleep Res"},{"key":"3275_CR4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1183\/09031936.00016808","volume":"33","author":"JL Pepin","year":"2009","unstructured":"Pepin JL, Viot-Blanc V, Escourrou P, Racineux JL, Sapene M, Levy P, Dervaux B, Lenne X, Mallart A (2009) Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur Respir J 33:1062\u20131067. https:\/\/doi.org\/10.1183\/09031936.00016808","journal-title":"Eur Respir J"},{"key":"3275_CR5","doi-asserted-by":"publisher","first-page":"690008","DOI":"10.3389\/fneur.2021.690008","volume":"12","author":"MR Bonsignore","year":"2021","unstructured":"Bonsignore MR, Pepin JL, Cibella F, Barbera CD, Marrone O, Verbraecken J, Saaresranta T, Basoglu OK, Trakada G, Bouloukaki I, McNicholas WT, Bailly S, Pataka A, Kvamme JA, Hein H, Mihaicuta S, Grote L, Fanfulla F (2021) Excessive daytime sleepiness in obstructive sleep apnea patients treated with continuous positive airway pressure: data from the European Sleep Apnea Database. Front Neurol 12:690008. https:\/\/doi.org\/10.3389\/fneur.2021.690008","journal-title":"Front Neurol"},{"key":"3275_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1513\/AnnalsATS.202006-696FR","volume":"18","author":"C Lal","year":"2021","unstructured":"Lal C, Weaver TE, Bae CJ, Strohl KP (2021) Excessive daytime sleepiness in obstructive sleep apnea: mechanisms and clinical management. Ann Am Thorac Soc 18:757\u2013768. https:\/\/doi.org\/10.1513\/AnnalsATS.202006-696FR","journal-title":"Ann Am Thorac Soc"},{"key":"3275_CR7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.5665\/sleep.5834","volume":"39","author":"S Garbarino","year":"2016","unstructured":"Garbarino S, Guglielmi O, Sanna A, Mancardi GL, Magnavita N (2016) Risk of occupational accidents in workers with obstructive sleep apnea: systematic review and meta-analysis. Sleep 39:1211\u20131218. https:\/\/doi.org\/10.5665\/sleep.5834","journal-title":"Sleep"},{"key":"3275_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.5664\/jcsm.7624","volume":"15","author":"C Stepnowsky","year":"2019","unstructured":"Stepnowsky C, Sarmiento KF, Bujanover S, Villa KF, Li VW, Flores NM (2019) Comorbidities, health-related quality of life, and work productivity among people with obstructive sleep apnea with excessive sleepiness: findings from the 2016 US National Health and Wellness Survey. J Clin Sleep Med 15:235\u2013243. https:\/\/doi.org\/10.5664\/jcsm.7624","journal-title":"J Clin Sleep Med"},{"key":"3275_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1124\/jpet.118.248120","volume":"366","author":"MG Baladi","year":"2018","unstructured":"Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A (2018) Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 366:367\u2013376. https:\/\/doi.org\/10.1124\/jpet.118.248120","journal-title":"J Pharmacol Exp Ther"},{"key":"3275_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.neubiorev.2021.09.020","volume":"131","author":"Y Alnefeesi","year":"2021","unstructured":"Alnefeesi Y, Tamura JK, Lui LMW, Jawad MY, Ceban F, Ling S, Nasri F, Rosenblat JD, McIntyre RS (2021) Trace amine-associated receptor 1 (TAAR1): potential application in mood disorders: a systematic review. Neurosci Biobehav Rev 131:192\u2013210. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.09.020","journal-title":"Neurosci Biobehav Rev"},{"issue":"suppl 1","key":"3275_CR11","doi-asserted-by":"publisher","first-page":"A329","DOI":"10.1093\/sleep\/zsac079.752","volume":"45","author":"H Gursahani","year":"2022","unstructured":"Gursahani H, Jolas T, Martin M, Cotier S, Hughes S, Macfadden W (2022) Preclinical pharmacology of solriamfetol: potential mechanisms for wake promotion [abstract 0756]. Sleep 45(suppl 1):A329. https:\/\/doi.org\/10.1093\/sleep\/zsac079.752","journal-title":"Sleep"},{"key":"3275_CR12","unstructured":"(2022) Sunosi\u00ae (solriamfetol) tablets Prescribing Information. Axsome Therapeutics, Inc., New York, NY, USA"},{"key":"3275_CR13","unstructured":"(2023) Sunosi\u00ae (solriamfetol) tablets Summary of Product Characteristics. Atnahs Pharma Netherlands B. V., K\u00f8benhavn S, Denmark"},{"key":"3275_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1164\/rccm.201806-1100OC","volume":"199","author":"PK Schweitzer","year":"2019","unstructured":"Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP (2019) Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial. Am J Respir Crit Care Med 199:1421\u20131431. https:\/\/doi.org\/10.1164\/rccm.201806-1100OC","journal-title":"Am J Respir Crit Care Med"},{"key":"3275_CR15","doi-asserted-by":"publisher","first-page":"zsz220","DOI":"10.1093\/sleep\/zsz220","volume":"43","author":"A Malhotra","year":"2020","unstructured":"Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo P, Mayer G, Sarmiento K, Baladi M, Chandler P, Lee L, Schwab R (2020) Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep 43:zsz220. https:\/\/doi.org\/10.1093\/sleep\/zsz220","journal-title":"Sleep"},{"key":"3275_CR16","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1007\/s12325-022-02249-4","volume":"39","author":"H Singh","year":"2022","unstructured":"Singh H, Hyman D, Parks GS, Chen A, Foley C, Baldys B, Ito D, Thorpy MJ (2022) Solriamfetol Titration and AdministRaTion (START) in patients with obstructive sleep apnea: a retrospective chart review and hypothetical patient scenario. Adv Ther 39:4359\u20134373. https:\/\/doi.org\/10.1007\/s12325-022-02249-4","journal-title":"Adv Ther"},{"key":"3275_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.sleep.2023.01.022","volume":"103","author":"Y Winter","year":"2023","unstructured":"Winter Y, Mayer G, Kotterba S, Benes H, Burghaus L, Koch A, Girfoglio D, Setanoians M, Kallweit U (2023) Solriamfetol real world experience study (SURWEY): initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany. Sleep Med 103:138\u2013143. https:\/\/doi.org\/10.1016\/j.sleep.2023.01.022","journal-title":"Sleep Med"},{"key":"3275_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14:540\u2013545","journal-title":"Sleep"},{"key":"3275_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1164\/rccm.201704-0672LE","volume":"197","author":"S Patel","year":"2018","unstructured":"Patel S, Kon SSC, Nolan CM, Barker RE, Simonds AK, Morrell MJ, Man WD (2018) The Epworth Sleepiness Scale: minimum clinically important difference in obstructive sleep apnea. Am J Respir Crit Care Med 197:961\u2013963. https:\/\/doi.org\/10.1164\/rccm.201704-0672LE","journal-title":"Am J Respir Crit Care Med"},{"key":"#cr-split#-3275_CR20.1","unstructured":"Twelve-week study of the safety (2024) and efficacy of JZP-110 in the treatment of excessive sleepiness in OSA [TONES3] [internet]. ClinicalTrials.gov identifier: NCT02348606"},{"key":"#cr-split#-3275_CR20.2","unstructured":"[cited July 12, 2024]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02348606. Accessed September 6"}],"updated-by":[{"DOI":"10.1007\/s11325-025-03321-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000}}],"container-title":["Sleep and Breathing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-025-03275-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11325-025-03275-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-025-03275-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:41:47Z","timestamp":1744188107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11325-025-03275-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3275"],"URL":"https:\/\/doi.org\/10.1007\/s11325-025-03275-6","relation":{},"ISSN":["1520-9512","1522-1709"],"issn-type":[{"value":"1520-9512","type":"print"},{"value":"1522-1709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the originally published version of this article, the article title was incorrectly given as \u201cPatients with obstructive sleep apnea in Germany.\u201d This has been corrected to read \u201cSURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.\u201d","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11325-025-03321-3","URL":"https:\/\/doi.org\/10.1007\/s11325-025-03321-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with applicable national and local requirements for good research study practices. Required country-specific documentation was reviewed and approved, per local regulations, before any patient chart data were included in the study. Because all patient chart data were de-identified and anonymous to the sponsor, informed consent was not required from patients, based on international regulations, including the General Data Protection Regulation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Y Winter has received honoraria for educational presentations and consultations from Angelini Pharma, Axsome Therapeutics, Avextra Pharma, Bayer AG, BIAL, Bioprojet, Bristol Myers Squibb, Eisai, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, LivaNova, Novartis, and UCB Pharma. G Mayer has received honoraria for consultation and educational presentations by Idorsia, Pharmanovia, and Takeda. H Benes and L Burghaus have nothing to disclose. S Floam is an employee of Axsome Therapeutics. G Parks is a former employee of Axsome Therapeutics. U Kallweit is on the advisory board at Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, and Takeda Pharma. He is also a consultant to AOP Orphan Pharmaceuticals, Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, and Takeda Pharma and has accepted institutional grants\/research support from Bioprojet Pharma, Harmony Biosciences, and Jazz Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"112"}}